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Abstract
Increasing evidence suggests that chromatin modifications have important roles in modulating constitutive or alternative
splicing. Here we demonstrate that the PWWP domain of the chromatin-associated protein Psip1/Ledgf can specifically
recognize tri-methylated H3K36 and that, like this histone modification, the Psip1 short (p52) isoform is enriched at active
genes. We show that the p52, but not the long (p75), isoform of Psip1 co-localizes and interacts with Srsf1 and other
proteins involved in mRNA processing. The level of H3K36me3 associated Srsf1 is reduced in Psip1 mutant cells and
alternative splicing of specific genes is affected. Moreover, we show altered Srsf1 distribution around the alternatively
spliced exons of these genes in Psip1 null cells. We propose that Psip1/p52, through its binding to both chromatin and
splicing factors, might act to modulate splicing.
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Introduction
Pre-mRNA splicing occurs co-transcriptionally [1], whilst the
nascent transcript is still associated with the chromatin template.
However, until recently there has been little consideration of how
chromatin structure might influence the control of splicing. Initial
studies indicated a link between promoters and alternative splicing
[2–4] and this has been extended to histone modifications enriched
at promoters. For example, Gcn5 mediated histone acetylation at
promoters in yeast has been shown to facilitate recruitment of
splicing factors [5] and mammalian GCN5-containing complexes
interact with pre-mRNA splicing factors [6]. The chromatin
remodeller CHD1, which recognises a histone mark (H3K4me3)
enriched at active promoters, also interacts with spliceosome
components and affects the rate of mRNA splicing [7].
A link between the rate of transcriptional elongation and
splicing [8–10] has led to a consideration of how chromatin
structure within the body of genes might also influence splicing.
Increased levels of histone acetylation in gene bodies lead to exon
skipping, likely through enhanced RNA polymerase II processivity
[11]. Conversely, HP1c, which binds to H3K9me3, favors
inclusion of alternative exons, possibly by decreasing RNA
polymerase II elongation rate [12].
Trimethylation of H3 at lysine 36 (H3K36me3) is enriched at
exons, particularly those of highly expressed genes [13–17] and its
level at alternatively spliced exons is reported to correlate with
their inclusion into the spliced transcript [13]. An explanation for
this may come from observations that pre-mRNA splicing itself
affects the deposition of this histone modification [18,19]. A direct
link between H3K36me3 and an effect on mRNA splicing comes
from the observation that MRG15, a protein whose chromodo-
main can recognise H3K36me3, recruits polypyrimidine tract
binding protein (PTB) to alternatively spliced exons [20]. It was
not clear whether this is a unique interaction or whether there are
other systems that connect H3K36me3 to alternative splicing.
PC4 and SF2 interacting protein 1 (Psip1) has been implicated
in transcriptional regulation and mRNA splicing in vitro [21], but
its function in vivo is poorly understood. It has been implicated in
developmental gene regulation [22] and in guiding the integration
of human immunodeficiency virus (HIV) into the host genome
[23–26]. Psip1 encodes two protein isoforms - p52 and p75 -
generated by alternative splicing within intron 9, and whose
relative levels vary between tissues [21,27]. The p75 isoform, also
known as lens epithelium derived growth factor (Ledgf), has a C-
terminal integrase binding domain (IBD) (Figure 1A) that binds
the integrases of HIV-1 and other lentiviruses, preventing their
degradation by the proteosome [28] and tethering them to host
chromosomes [28–33]. In Psip1 mutant cells, HIV/lentivirus
infection is impaired and sites of viral integration into the host
genome are altered [24–26]. Though the normal cellular function
of Psip1/p75 has not been established, the IBD binds to RAM2/
JPO2 - a myc-associated transcriptional regulator [34,35] and p75
is tethered, via Menin and in an IBD-dependant manner, to MLL
H3K4 histone methyltransferase [36].
The p52 isoform of Psip1 lacks the IBD (Figure 1A) and does
not interact with Menin. Instead, Psip1/p52 has been purified
with PC4 transcriptional co-activator [37], and had been shown to
immunoprecipitate (IP) with, and to modulate the activity of, the
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indicating that it might have a role in mRNA processing.
Here we show that the N-terminal PWWP domain, common to
both Psip1 isoforms, can specifically recognize H3K36me3 and,
that like H3K36me3, Psip1/p52 is enriched at expressed genes and
often at the downstream exons of those genes. We demonstrate that
Psip1/p52, but not p75, also interacts with proteins known to be
involved in splicing and RNA processing and co-localizes with
splicing factor-enriched speckles in the nucleus. Furthermore, we
show that there is altered alternative splicing in Psip1 mutant cells
andthat this is attributableto loss offunction ofthe p52isoform.We
demonstrate altered association of Srsf1 with the genome in the
absence of functional Psip1, including around some exons whose
inclusion or exclusion into mRNA is altered in Psip1 mutant cells.
We propose that Psip1/p52 provides a new example of commu-
nication between chromatin and the regulation of mRNA splicing.
Results
Psip1 PWWP domain can bind to H3K36me3
GFP-tagged full-length, and b-gal tagged gene-trap, versions of
Psip1/p75 have been reported on mitotic chromosomes
Figure 1. Psip1 PWWP domain binds to H3K36me3. A) Diagram of p52 and p75 Psip1 isoforms showing the position of the; PWWP domain, AT
hook-like domains (hatched box), C-terminal 8 a.a. unique to p52 (black box), and the p75-specific IBD. Vertical arrow indicates the site of gene trap
integration in Psip1
gt/gt [22]. Horizontal lines indicate the position of epitopes recognized by antibodies A300-847 and A300-848. B) Peptide array
containing 384 histone tail modification combinations incubated with GST-Psip1-PWWP and detected with aGST. Spots corresponding to unmodified
H3 26–45 peptide (arrow) and H3K36me3 (arrowhead) are indicated. C) Binding specificity (calculated from the intensity of the histone peptide
interaction) of Psip1-PWWP (y axis) to the top list of histone modifications arranged according to decreasing specificity (x axis). Data for all the
modifications are provided in Table S1. D) Immunoblot of biotinylated H3K36me3 peptide pull-down detecting GST-p52 with aGST antibodies.
Corresponding unmodified histone H3 peptide served as control and GST-p52 was loaded as input. E) Immunoblot of A300-847 IPs with antibodies
detecting; unmodified H3, H3K36me3, H3K9me2 and H3K4me3. IgG served as control and 5% of NIH3T3 nuclear extract was loaded as input.
doi:10.1371/journal.pgen.1002717.g001
Author Summary
The regulated processing of mRNAs by splicing of exons
and introns has the potential to increase the information
content of the genome. Various splicing factors have been
identified whose binding to cis-acting sequences can
influence whether an alternative exon is included or
excluded (skipped) in the mature mRNA. However,
increasing evidence suggests that the chromatin template
also has an important role in modulating splicing. Here we
identify a chromatin-associated protein Psip1/Ledgf that
can bind to a histone modification enriched at active
genes and that can also interact with other proteins
involved in mRNA splicing. Loss of Psip1 reduces the
chromatin association of specific splicing proteins and
alters the pattern of alternative splicing. We propose that
Psip1, through its binding to both chromatin and splicing
factors, might act to modulate splicing.
Psip1/p52 and Alternative Splicing
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(Figure 1A) is required for chromatin association [41]. PWWP
belongs to the Tudor (Royal) family of protein domains, which are
known to bindmethylated lysines, includingin histones [42] and the
PWWP domains of Brpf1, Dnmt3a, MSH-6, NSD1, NSD2 and N-
PAC have been shown to specifically bind H3K36me3 [43–45].
To determine if the Psip1 PWWP domain directly interacts with
modified histone tails, we used histone tail peptide arrays
containing in total 59 different modifications of H3, H4, H2A,
and H2B tails in 384 different combinations. In two independent
experiments, we observed that GST-tagged Psip1 PWWP domain
bound H3K36me3 with high specificity - signal from H3K36me2,
H3K36me and corresponding unmodified peptide spots were not
above background (Figure 1B and 1C, Table S1). Direct binding
of p52 with H3K36me3 was confirmed by peptide pulldown
(Figure 1D). Immunoblotting with antibodies recognizing different
H3 methylation states confirmed a specific enrichment of
H3K36me3 in Psip1 IPs from nuclear extracts (Figure 1E).
Psip1/p52 is enriched at expressed genes
We assessed the genomic distribution of Psip1 in mouse
embryonic fibroblasts (MEFs) by chromatin immunoprecipitation
(ChIP) using aPsip1 antibody A300-847 (see below) and hybrid-
ization to a custom tiling array. The hybridization pattern was
compared to that from H3K36me3 and H3K4me3 ChIPs.
The large-scale distributions of H3K36me3 and Psip1/p52
were similar to each other and both appeared to be enriched at
active genes (Figure 2A). Across the entire array, levels of both
Psip1/p52 and H3K36me3 were significantly higher at active
genes than inactive genes or intergenic regions, and furthermore
were especially enriched at the exons compared to the introns of
expressed genes (p,0.05) (Figure 2B). Visual inspection of specific
genes revealed a similar distribution of Psip1/p52 and H3K36me3
at some downstream exons (Figure 2C and 2D), distinct from the
peak of H3K4me3 at promoters. However, there is also evidence
for some enrichment of Psip1/p52 near the transcription start sites
(TSSs) suggesting multiple modes of Psip1 association to chroma-
tin. Correlation between the distribution of Psip1/p52 and
H3K36me3 (Spearman’s rank correlation coefficient r=0.38,
p,0.05) was stronger than that between Psip1/p52 and
H3K4me3 (r=20.05) or between H3K36me3 and H3K4me3
(r=0.013).
Splicing proteins interact with Psip1/p52
To determine whether there are other interacting partners for
Psip1 isoforms, apart from H3K36me3, we performed immuno-
precipitation with two different antibodies.
Antibody A300-847 was raised against an epitope present in
both p52 and p75 (a.a. 225–275) (Figure 1A) and indeed detects
both isoforms by immunoblot (Figure 3A). However, A300-847
efficiently IPs the Psip1 p52 isoform, but not p75 (Figure 3B). This
is likely due to masking of the A300-847 epitope in the p75 tertiary
structure. In agreement with this, Ge et al [38] also reported that
antibodies generated against recombinant p52 could recognize
both p52 and p75 by immunoblot, but could not IP Psip1/p75
under native conditions.
In addition to Psip1/p52 itself, a large number of other proteins
were co-immunoprecipitated from NIH3T3 cells using A300-847
(Figure S1A). Mass spectrometry revealed that <95% of them are
known to function in pre-mRNA processing. Grouping the mascot
hits according to their known function(s) and/or key domains
revealed; SR proteins, DEAD/H box helicases, proteins of the U5
snRNP, hnRNP proteins, and other proteins known to function in
pre-mRNA processing (Table 1). Apart from these, a few other
transcription related proteins were identified. In agreement with
the report of its co-purification with p52, Srsf1 was one of the
major hits [38]. The specificity of A300-847 antibody for wild-type
(wt) Psip1/p52 is evidenced by the absence of immunoprecipita-
tion of Srsf1 and other SR proteins in extracts prepared from
MEFs homozygous for a gene-trap integration into Psip1 (Psip1
gt/
gt) (Figure S1A and S1B) in which the A300-847 epitope is 39 to the
site of gene trap integration, and so is absent from the resulting
fusion protein (Figure 1A) [22].
Antibody A300-848 specifically recognizes the extreme C-
terminus – amino acids (a.a.) 480 to 530 - of Psip1/p75 (Figure 1A)
and so detects endogenous p75, but not p52, in immunoblots and
IPs (Figure 3A and 3B). Only a few transcription related proteins,
in addition to p75 itself, were IP’ed from nuclear extracts by A300-
848 (data not shown).
These data indicate a cellular link between Psip1/p52 and the
splicing machinery. Immunoblotting of the IP from RNase treated
nuclear extracts indicated that Psip1/p52 interacts mainly with the
hypophosphorylated form of SRSF1 (Figure 3C). Phosphorylation
levels of SR proteins are known to modulate alternative splicing
and alter SR protein distribution in relative to splicing-factor
enriched nuclear speckles [46–48]. GST-p52 pull down of T7-
SRSF1 (over expressed HEK-293T cells), confirmed direct
interaction of Psip1/p52 with SRSF1 and that the Psip1 PWWP
domain is not sufficient for this (Figure 3D). Furthermore, GST-
p52 pulldown of SRSF1 mutants which mimic hypo (RG) and
hyper (RD) phosphorylation (serine residues within RS/SR
dipeptide repeats of RS domain substituted with Glycine: RG or
Aspartic acid: RD) [49] shows higher affinity of Psip1/p52 for
hypophosphorylated SRSF1 compared to the hyperphosphory-
lated form (Figure 3E).
GST pulldown also confirms interaction with SRSF3, but shows
that Psip1/p52 does not simply interact non-specifically with all
SR proteins, since there is no direct interaction with SRSF2
(SC35) (Figure 3E). Identification of Srsf2 by mass spectrometry in
the A300-847 immunoprecipitate presumably is the result of
indirect association with other splicing proteins (Table 1).
Association of SRSF1 to H3K36me3 marked chromatin
requires p52
Unphosphorylated SRSF1 has been reported to associate with
chromatin, especially the H3 tail and to be sensitive to H3 tail
post-translational modifications [50]. To investigate whether
absence of Psip1 causes any loss of Srsf1 chromatin association
in vivo, chromatin purified by ChIP for H3K36me3 was analyzed
by immunoblotting. Levels of Srsf1 associated with H3K36me3
modified chromatin were greatly reduced in Psip1
2/2 MEFs cells
that do not have detectable Psip1/Ledgf [25], compared to wild
type (Figure 3F). As controls, the levels of H3K36me3 associated
Ptb and Srsf2 were not changed in the Psip1
2/2 IPed chromatin
compared to wild type, These results confirm that Psip1/p52
specifically recruits Srsf1 to H3K36me3 chromatin in vivo, but not
Ptb, which has been shown to be recruited to H3K36me3
chromatin through MRG-15 [20].
To investigate whether SRSF1 alone can bind to H3K36me3 in
vitro, or whether this occurs via interaction with Psip1, we pulled-
down HeLa core histones with T7-SRSF1, with or without
addition of Psip1/p52. Immunoblotting with antibodies recogniz-
ing different methylated states of H3 revealed a specific
enrichment of H3K36me3 in the presence of Psip1/p52 compared
to SRSF1 alone (Figure 3G). These results suggest that Psip1/p52
can aid the recruitment of specific splicing factors, including
SRSF1, to H3K36me3 modified chromatin.
Psip1/p52 and Alternative Splicing
PLoS Genetics | www.plosgenetics.org 3 May 2012 | Volume 8 | Issue 5 | e1002717Figure 2. Genomic distribution of Psip1/p52 and H3K36me3. A) Mean log2 ChIP:input for Psip1/p52 and H3K36me3 in MEFs for an
approximately 1.2Mb genomic window from mouse chromosome 5. n=4 (3 biological and 1 technical replicate). B) Box plots showing the
distribution of log2 ChIP:input for Psip1/p52 and H3K36me3 across exons and introns of expressed or non-expressed genes. Data are deposited in
NCBI GEO (Accession no. GSM697402-GSM697411). C, D) Mean log2 ChIP:input for Psip1/p52 and H3K36me3 in MEFs at (C) c-Myc and (D) Xist loci.
H3K4me3 is also shown for XIST. Filled boxes indicate the positions of exons. n=4 (3 biological and 1 technical replicate) for H3K36me3 and Psip1.
NCBI GEO accession number for array platform is GPL13276. n=2 biological: replicates for H3K4me3.
doi:10.1371/journal.pgen.1002717.g002
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Given the preponderance of splicing/RNA-binding proteins co-
immunoprecipitating with Psip1/p52 but not p75 (Figure 3 and
Table 1), we investigated the nuclear localizations of Psip1
isoforms. Antibody A300-848 revealed that, as for Psip1
gt/gt [22],
endogenous p75 is associated with chromosomes in mitotic cells
(Figure 4A) and is generally distributed in the nucleoplasm at
interphase.
Immunostaining with A300-847 also showed association with
mitotic chromosomes, but at interphase revealed numerous
nuclear foci reminiscent of splicing-factor enriched nuclear
speckles [51] (Figure 4A). Co-immunostaining for Psip1/p52/
Figure 3. Immunoprecipitation of Psip1/p52 and p75. A) Immunoblot of NIH 3T3 nuclear extract with antibodies; A300-848 which recognizes
only the p75 isoform of Psip1, and A300-847 which detects both p52 and p75. B) IPs with IgG, A300-847 and A300-848 from NIH 3T3 nuclear extracts,
immunoblotted with antibodies recognizing p75 (A300-848) or p52 (A300-847). Input is 5% total extract. C) Immunoblot of A300-847 IPs with aSRSF1.
IP was also performed in the presence of RNase A. Input is 10% of total extract and IgG served as a control. D) In vitro pulldown of 293T cell expressed
T7-SRSF1 using GST-p52 and Psip1-PWWP and immunoblotted with aT7. Input is 5% of T7-SRSF1 and GST alone is control. E) In vitro pulldown with
GST-p52 of; T7-SRSF1 and mutants that mimic its hypo-(RG) and hyper-phosporylation (RD), T7-SRSF3 and GFP-SRSF2. Immunoblotting was with aT7
or aGFP. F) ChIP with aH3K36me3 from wild-type (wt) and Psip1
2/2 MEFs immunoblotted with antibodies detecting Srsf1, Srsf2, Srsf3, PTB, Psip1 and
H3K36me3. G) In vitro pulldown of HeLa core histones by T7-SRSF1 in the presence or absence of Psip1/p52 and immunoblotted with antibodies
detecting pan H3, H3K36me3, H3K9me2 and H3K4me3.
doi:10.1371/journal.pgen.1002717.g003
Psip1/p52 and Alternative Splicing
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ID
Protein
name Alias Protein domains Functions Peptides Mass (kDa)
SR proteins
gi 5902076 Srsf1 * SF2/ASF RRM x2, RS Constitutive and AS 42 27
gi 3153821 Srrm 1 * POP101/Srm160 RS, PWI Constitutive and AS 30 101
gi 22122585 Srsf7 9G8 RRM, RS Constitutive and AS 25 27
gi 6755478 Srsf2 SC-35 * RRM, RS Constitutive and AS 25 35
gi 3929369 Srsf5 SRp40 RRM x2, RS Constitutive and AS 17 31
gi 114152161 Srrm2 SRm300 RS Constitutive and AS 17 295
gi 9622185 Acinus Acin1 RRM, RS, SAP mRNA splicing regulation, apoptosis, EJC 16 150
gi 12844972 Srsf 3 Srp20 RRM, RS Constitutive and AS 16 19
gi 27461725 Pinin Pnn RS AS regulator 11 82
gi 4759098 Srsf10* Tra2b RRM, RS x2 Splicing activator 9 33
gi 13278367 Rbm39 Rnpc2 RRM x3, RS AS regulation 9 47
gi 13385016 Srsf9 SRp30 RRM x2, RS Constitutive and AS 8 25
gi 124487333 Ppig SRCyp RS, PPIase Regulates localisation of SR proteins 6 88
gi 1399464 Prpf4b Prpk RS, kinase mRNA splicing 6 116
gi 4001720 SRp38 Nssr 1 RRM, RS General splicing repressor 3 31
gi 122890231 Srsf4 Srp75 RRM x2, RS Constitutive and AS 2 56
DExD/H box helicases
gi 28076989 DDX54 DP97 DEAD, helicase Transcription regulation 43 98
gi 148707489 DHX 9 NDH2 DsRM, DEAD, helicase Transcription regulation, mRNA splicing 30 132
gi 2500527 DDX5 * RNA helicase p68 DEAD, helicase mRNA splicing, microRNA processing 27 69
gi 6753620 DDX3X DAP88 DEAD, helicase mRNA splicing, RNA export, microRNA processing,
translation
27 73
gi 16716475 DDX 50 RH II/Gu DEAD, helicase Ribosome biogenesis, transcription co-factor 25 82
gi 27371129 DDX10 HRH-J8 DEAD, helicase Ribosome biogenesis 24 78
gi 110835726 DHX15 Prp43 DEAD, helicase mRNA splicing, microRNA processing 27 73
gi 73620772 DDX41* Abstrakt DEAD, helicase, C2HC Zn
finger
mRNA splicing 19 70
gi 25141235 DDX3Y DBY DEAD Box mRNA splicing, microRNA processing, RNA export,
translation
14 73
SnRNPs
gi 40018610 U5-200KD BRR2 DEAD, helicase, sec63 mRNA splicing, U5 snRNP complex 13 246
gi 124430514 U5 100K * DDX 23/Prp28 RS, DEAD, helicase mRNA splicing, U5 snRNP complex 12 42
gi 19527174 SF3B3* Sf3b(130) CPSF_A mRNA splicing, U2 snRNP complex 10 136
gi 21539655 U5-102 kDa Prp6 HAT repeats mRNA splicing, U5 snRNP complex 6 107
hnRNPs
gi 21313308 hnRNPm KIAA4193 RRM Pre-mRNA processing 17 78
gi 3914804 hnRNPg Rbmx RRM Pre-mRNA processing 10 42
gi 123778087 hnRNPu like MLF1ANP RRM, SAR DNA binding Pre-mRNA processing 4 85
gi 13384620 hnRNPk TUNP KH domains Pre-mRNA process 5 51
Other proteins likely to be involved in RNA processing
gi 54607128 RRP5 PDCD11 S1, HAT rRNA processing 98 209
gi 29747798 Rbm 12b RBM 12Ba RRM x5 Unknown 12 97
gi 188497644 Noc3 Fad24 mRNA splicing, transcription 11 93
gi 83921589 Fxr2 KH 10 74
gi 4835742 FXR1 Fxr1p KH translation 8 64
gi 29747807 Safb2 * SAF-B2 SAP, RRM Transcription and splicing 4 114
gi 34098365 NRF ITBA4 ds RNA binding, G patch Transcription regulation 11 78
Psip1/p52 and Alternative Splicing
PLoS Genetics | www.plosgenetics.org 6 May 2012 | Volume 8 | Issue 5 | e1002717Table 1. Cont.
ID
Protein
name Alias Protein domains Functions Peptides Mass (kDa)
Other proteins
gi 23503105 NOC2L nucleolar transcription corepressor 30 86
gi 18539461 NOL6 nucleolar 30 128
gi 2645205 Mybbp1A armadillo Transcription regulation 28 150
gi 9790013 AATF Nucleolus, apoptosis, transcription regulation 25 59
gi 71979675 LAS1L Ribosome biogenesis 23 88
gi 83921589 FMR2 10 74
Proteins identified by mass spectrometry of p52 IPs (200 mM KCl).
*indicates known proteins of the ‘spliceosomal complex C’. Data on protein domains and putative protein functions were taken from http://npd.hgu.mrc.ac.uk/.
doi:10.1371/journal.pgen.1002717.t001
Figure 4. Sub-cellular localization of Psip1/p52 and p75. A) Immunofluorescence and wide-field epifluorescence microscopy on human cells
with; (upper row) p75-specific antibody A300-848, (lower row) A300-847 which can recognize both p52 and p75. DNA was counterstained with DAPI.
B) Co-immunofluorescence of Psip1/p52 (green/A300-847) and SRSF2 (red) analyzed by confocal microscopy in untreated (upper row), or actinomycin
D (ActD) treated cells. C) Co-immunofluorescence of Psip1/p75 (green/A300-848) and SRSF2 (red) in ActD treated cells and analyzed by confocal
microscopy.
doi:10.1371/journal.pgen.1002717.g004
Psip1/p52 and Alternative Splicing
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speckles, confirmed this (Figure 4B). Splicing-factor enriched
nuclear speckles become larger and less numerous upon the
inhibition of transcription with actinomycin D [40]. Concomi-
tantly, Psip1/p52 also became redistributed to these foci. In
contrast, there was no correspondence between the sub-nuclear
distribution of Psip1/p75 and splicing-factor enriched nuclear
speckles (Figure 4C).
Loss of Psip1/p52 affects alternative splicing
To identify whether there are specific exons whose splicing in
vivo might be affected by Psip1/p52, we analyzed patterns of
alternative splicing in RNA prepared from primary MEFs from
three different Psip1
gt/gt and corresponding wild type littermate
embryos. Psip1
gt/gt mutant mice were generated from ES cells with
a gene trap integrated between exons 8 and 9 of Psip1. This results
in the production of a protein in which only the N-terminal 208
a.a. of Psip1 are present (arrowed in Figure 1A) and are fused to
the b-geo reporter [40]. We used a custom Affymetrix microarray
containing 40,443 exon junction probe sets derived from 7,175
genes with one or more predicted alternative transcripts and
analyzed the data with ASPIRE 3 software [52]. Splicing changes
were detected in 95 alternative exons with a score that, in our past
experience, can be validated by RT-PCR with high (.90%
success; DI rank $1, or #21) [53,54]. Out of these, 58 exons,
from 55 genes, appeared to have decreased inclusion in the mutant
MEFs and 37 exons, from 35 genes, had increased inclusion
(Table S2).
The gene-trap in Psip1
gt/gt is between exons 8 and 9 (Figure 1A)
[22] so the resulting mRNA lacks exons 9-15. This was evident
from the microarray results, which detected Psip1 exons 11 and 12
as those with the most decreased inclusion in the whole analysis
(Table S2). At the other extreme, the most increased inclusion of
alternative exons in Psip1
gt/gt was at Ptprc. In mutant cells,
increased alternative exon inclusion for Ptprc, Ppfibp, Rapgef6,
Rasgrp3 and Ogfrl1, all of which have a DI.1, and altered 39 splice
site utilization at alternative exon 4 of Sorb2 (DIo f,21), was
confirmed by semi-quantitative RT-PCR of RNA from primary
MEFs derived from three wild type and three Psip1
gt/gt litter mates
(Figure 5A). Primer pairs spanned across regions subject to
alternative splicing to generate PCR products of different sizes
dependent on exon skipping or inclusion (Table S3). A 2–3 fold
increase in the ratio of included:skipped exon bands was seen in
mutant cells compared to wild-type. The absence of alternative
splicing at the alternative exons of Csnk1d, Alg9 and Tpp2 exon 24,
which were not detectably altered in the microarray, was also
confirmed by RT-PCR (Figure 5B, 5D).
To examine the splicing of specific alternative exons, RT-PCR
was also carried out across specific constitutive exon - constitutive
exon junctions and across constitutive exon - alternative exon
junctions of Vcan, Tpp2 and Diap2 where microarray analysis had
indicated increased exon skipping in Psip1
gt/gt cells (DI#21) (Table
S2). This confirmed the decreased inclusion of alternatively spliced
exons in Psip
gt/gt cells (Figure 5C). To rule out the possibility of
amplification bias, RT-PCR using primers spanning constitutive
exons at either the 59 or 39 end of Tpp2, Vcan and Diap2 were
tested (Figure 5D).
Although the gene-trapped Psip1 protein produced in Psip
gt/gt
cells is truncated and co-localizes with concentrations of chromatin
instead of splicing factors [22,40], we wished to confirm a role for
Psip1 in the regulation of alternative splicing using an indepen-
dently derived mutant allele. Therefore, splicing patterns of
specific genes were also examined in Psip1
2/2 MEFs in which
deletion of Psip1 exon 3 leads to the absence of detectable Psip1/
Ledgf protein [25]. As for Psip1
gt/gt (Figure 5A and 5B) altered
patterns of splicing at Vcan, Tpp2,Diap2 and Sorb2 were detected in
RNAprepared fromPsip1
2/2MEFscomparedtowild-type controls
(Figure 5E).
Since the mutations in both Psip1
gt/gt and Psip1
2/2 affect both
p52 and p75 isoforms, we determined whether dysregulated
alternative splicing could be directly attributed to p52 rather than
p75 by complementing Psip1
2/2 MEFs with expression of either
p52 and p75 (Figure 5G). Only expression of p52 rescued the
changes in alternative splicing pattern in Psip1
2/2 cells. Expres-
sion of Psip1/p75 did not restore splicing patterns of the tested
genes (Figure 5E). Consistent with the microarray, RT-PCR of
alternative exons of Csnk1d, Alg9 and alternative exon 24 of Tpp2
were not significantly altered by loss of Psip1 (Psip1
2/2)o rb y
functional rescue of those cells with either p52 or p75 (Figure 5F).
Loss of Psip1/p52 alters Srsf1 localization
Our data suggest that the absence of Psip1/p52 alters the
splicing pattern of alternative exons and that this might be
mediated by perturbed association of splicing factors at specific
genomic loci. SR proteins such as SRSF1 can affect alternative
splicing patterns through their recruitment to both alternatively
and constitutively spliced exons [55]. Therefore, we examined the
enrichment of H3K36me3, Psip1/p52, and Srsf1 across some
gene loci subject to alternative splicing, by ChIP and hybridization
to a custom microarray encompassing 8.2 megabases of the mouse
genome including loci whose splicing pattern we have shown
(Figure 5) is altered in Psip1
gt/gt cells. In addition Srsf1 binding was
analyzed by ChIP from cells lacking Psip1 (Psip1
2/2 MEFs)
(Figure 6). The correlation between sites of Srsf1 localization and
the Psip1 bound sites in wild-type cells (r=0.35 p,0.05), was
reduced (r=0.25) in Psip1
2/2 cells. In Psip1
2/2 cells Srsf1
binding was lost from the 59 side of Vcan exon 7 (Figure 6A), whose
inclusion into processed mRNA is reduced in Psip1
gt/gt cells
(Figure 5). Similarly, at Diap2 Srsf1 binding in Psip1
2/2 cells was
lost to the 39 side of exon 5 (Figure 6B) whose inclusion is reduced
in Psip1
gt/gt cells (Figure 5B).
However, the affects of Psip1 loss on Srsf1 chromatin binding
are complex. At Ppfibp1, where there is increased alternative exon
inclusion in Psip1
gt/gt cells (Figure 5), sites of Srsf1 binding seems
displaced toward the alternatively spliced exon 10, and away from
the downstream constitutively spliced exon 11 in mutant cells
(Figure 6C). This likely reflects a shift in the balance between
different modes of Srsf1 recruitment across this locus in the
absence of Psip1.
Discussion
Tri-methylation of H3K36 is elevated in the expressed exons
compared to introns, which suggested it is linked to splicing. A
recent report showed specific recruitment of the splicing factor
PTB to H3K36me3 modified chromatin at the FGFR2 gene via
MRG15 [20]. It was not clear whether other similar proteins exist
to recruit different splicing factors to H3K36me3 modified
nucleosomes. Our results suggest that there is a more extensive
family of chromatin proteins which can bind to H3K36me3 and
also recruit splicing factors to facilitate alternative splicing.
However, recent investigations [18,19] also propose a plausible
but not mutually exclusive model, in which splicing modulates the
level of H3K36me3. This suggests that there is extensive interplay
between H3K36me3 chromatin modification and alternative
splicing.
We demonstrate that the short (p52) isoform of Psip1 modulates
the inclusion or exclusion of alternative exons in specific mRNAs,
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in pre-mRNA splicing. Despite containing almost all the a.a.
residues of p52, the longer (p75) Psip1 isoform neither co-IPs, nor
co-localizes, with splicing related proteins (Figure 4). This, together
with the inability of the A300-847 antibody to IP p75, even though
its epitope is present in the protein sequence and recognized in
denatured p75 by immunoblot (Figure 3), suggests that protein
folding of Psip1/p75 occludes both the A300-847 epitope and the
region capable of interaction with splicing factors. Differential
localization and interaction with the transcriptional regulation
machinery or with splicing proteins has previously been reported
for different isoforms of another protein – WT1 [56–58].
We add Psip1 to the recently identified group of PWWP-
containing proteins - Brpf1, Dnmt3a, MSH-6, NSD1, NSD2 and
N-PAC - that have been shown to be able to bind H3K36me3
[43–45] (Figure 1 and Figure 2). This establishes the PWWP
members of the ‘royal’ family of protein domains as reader of this
histone modification, that has been associated with the exons of
active genes [13–16,59] and whose deposition onto chromatin has
recently been linked to the process of splicing itself [18,19].
MRG15 uses a chromo-domain for methylated histone binding
[20]. The chromo-domain, like PWWP, is also a royal family
protein domain [42], but the chromo-domain of MRG15 is
structurally more similar to the PWWP domain of DNMT3b than
to that of more typical chromo-domain proteins that recognize
H3K9me3 or H3K27me3 [60].
Psip1/p75 was demonstrated to be important for guiding HIV/
lentiviral integration to the body of genes [24–26]. Our
demonstration that the N-terminal PWWP domain, shared by
both p52 and p75 Psip1 isoforms, recognizes and binds to
H3K36me3 provides a mechanistic explanation for this pattern of
HIV integration.
There is a growing awareness of the interactions between
splicing factors and RNA polymerase II elongation [61] and
emerging evidence now highlights the role of histone modifications
in this process. At gene promoters, the chromo-domains of CHD1
recognize H3K4me3 [62,63] and CHD1 interacts with the SF3a
subcomplex of the U2 snRNP to then facilitate mRNA splicing
post-initiation [7]. Similarly, in yeast, the histone acetyltransferase
GCN5, found at the promoter regions of active genes, also
interacts with components of the U2 snRNP [5]. MRG15 and
Psip1/p52 now provide two examples of H3K36me3 binding
proteins that can influence the recruitment of splicing components
to chromatin.
MRG15 interacts with the RNA–binding protein PTB to
regulate alternative splicing [20]. In contrast, we found interac-
tions between Psip1/p52 and; several SR-containing proteins –
including Srsf1 (Figure 3 and Table 1), components of the U5
snRNP and other proteins involved in RNA processing. Further-
more, we show that the absence of functional p52 affects alternative
splicing of defined endogenous genes in vivo (Figure 5) and alters
the pattern of Srsf1 binding across alternatively spliced gene loci
(Figure 6).
Differential expression of SR proteins is important for tissue-
specific alternative splicing and is abundant in brain and testis
[64,65] where, compared to other tissues, mRNA for the p52
isoform of Psip1 is also at high levels compared to that of p75 [21].
Amongst other Psip1 co-immunoprecipitating proteins are
many DExD/H box family putative RNA helicases. One of these
is DDX10 which, like Psip1/Ledgf, is found as a fusion partner
with Nup98 in myeloid leukaemias and myelodysplastic syndromes
[66–69], perhaps indicative of their function in a common
pathway that is mis-regulated in these malignancies. The presence
of the H3K36 methyltransferase NSD1 as another Nup98 fusion
partner [70] [71] suggests that the splicing-H3K36me3 connection
might be implicated in the aetiology of these myeloid disorders.
Materials and Methods
Histone tail peptides arrays and peptide pulldown
A modified histone peptide array (Active motif, #13005) was
blocked in TBST buffer (10 mM Tris/HCl pH 8.3, 0.05%
Tween-20, 150 mM NaCl) containing 5% non-fat dried milk at
4uC overnight. The membrane was washed with TBST for 5 min,
and incubated with 10 gM purified GST-tagged Psip1 PWWP
domain, or GST protein alone, at room temperature (rt) for 1 h in
interaction buffer (100 mM KCl, 20 mM HEPES pH 7.5, 1 mM
EDTA, 0.1 mM DTT, 10% glycerol). After washing in TBST, the
membrane was incubated with goat a-GST (GE Healthcare #27-
4577-01, 1:5000 dilution in TBST) for 1 h at rt. The membrane
was then washed 36 with TBST for 10 min each at rt and
incubated with horseradish peroxidase conjugated a Goat
antibody (Invitrogen #81-1620 1:12000 in TBST) for 1 h at rt.
The membrane was submerged in ECL developing solution
(Pierce, #32209), imaged (Image-quant, GE Healthcare) and the
data quantified using array analyzer software (Active motif).
Biotinylated histone H3 (Ana spec 64440-025) and H3K36me3
(Ana spec 64441-025) peptides coupled to Streptavidin magnetic
beads (Invitrogen 656-01), and were used to pull-down GST-p52 as
described (http://www.epigenome-noe.net/WWW/researchtools/
protocol.php?protid=46).
Cloning, expression, and purification of proteins
Mouse GST-p52 and GST-PWWP (a.a. 1–97), were cloned into
pDEST-PGEX6P. Proteins were expressed in BL21 Codonplus
E.coli and purified on glutathione sepharose using standard
protocols.
Human SRSF1 and Human Psip1/p52 open reading frames
were cloned into pCG-T7 and pEGFP vector with CMV
promoters. pIRES2-eGFP-p52-HA and pIRES2-eGFP-p75-HA
were kindly gifted by Prof. Alan Engelman (Dana-Farber Cancer
Institute).
Figure 5. Alternative splicing in Psip1
gt/gt cells. RT-PCR to detect; exon inclusion (In) or skipping (Skip) of (A); Ptprc, Ppfibp1, Rapgef6, Rasgrp3,
Ogfrl, and Sorb2 all of which showed evidence for altered alternative splicing in array analysis, or (B) Csnk1d and Alg9, which were unchanged in the
array, in RNAs prepared from wt and Psip1
gt/gt primary MEFs. C) Specific exon-exon junctions (constitutive-constitutive or constitutive-alternative) of
Vcan, Tpp2 and Diap2 in wt and Psip1
gt/gt MEFs. D) Specific exon-exon junctions (constitutive-constitutive) of Vcan (59 exons) and Diap2 (39exons) and
constitutive-constitutive (59) and constitutive-alternative of Tpp2 alternative exon 24 in wt and Psip1
gt/gt MEFs. E) Specific exon-exon junctions
(constitutive-constitutive or constitutive-alternative) of Vcan, Tpp2 and Diap2; exon inclusion (In) or skipping (Skip) of Sorb2 in wt and Psip1
2/2 MEFs,
and after transfection of p52 or p75 Psip1 into Psip1
2/2 MEFs. F) Exon inclusion (In) or skipping (Skip) of; Csnk1d Alg9, and constitutive-constitutive
(59) and constitutive-alternative of Tpp2 alternative exon 24 in RNAs prepared from wt and Psip1
2/2 MEFs, and after transfection of p52 or p75 Psip1
into Psip1
2/2 MEFs. Sequence and position of primer pairs for each exons are listed in Table S3. Below the gels in panels A to F, the mean ratio of
alternative:constitutive exon (+/2 s.e.m.) is shown for three biological replicates. G) Immunoblots of proteins using A300-847 antibodies to detect
p75 and p52 in wt and Psip1
2/2 MEFs, also Psip1
2/2 MEFs transfected with p52 (Psip1
2/2 p52Res) and p75 (Psip1
2/2 p75Res). Immunoblot with Pcna
served as a loading control.
doi:10.1371/journal.pgen.1002717.g005
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Immunoblotting was performed with the following antibody
dilutions A300 847(1:2000), A300-848 (1;3000), aH3K36me3
(Abcam AB9050,1:500). aH3K9me2 (Abcam ab7312,1:500)
aH3K4me3 (Millipore 07-473, 1:500), aPan H3 (Abcam Ab
1791) aSRSF1 (1:300), aSRSF1 (Invitrogen 32-4500 1:2000)
aPCNA (Santa Cruz, Sc56) aT7 (Novagen, 65922), Detection was
by ECL.
Cell culture and transfection
Mouse embryonic fibroblast (MEF) lines were derived from 13.5
day old Psip1
gt/gt embryos and their corresponding wild-type
littermates [22]. They were maintained for three passages in
DMEM supplemented with 15% Fetal calf serum (FCS), non-
essential amino acids, sodium pyruvate, L-glutamine, and Penicil-
lin/Streptomycin and cultured at 37uC.
Psip1
2/2 and corresponding wild-type MEFs (gift of Alan
Engelman) [25] were maintained in DMEM supplemented with
10% FCS and Pencillin/Streptomycin. They were transfected with
Lipofectamine and GFP
+ve FACS-sorted cells were harvested after
72 hrs.
Chromatin immunoprecipitation
MEFs were harvested by trypsinizing and fixed immediately
with 1% formaldehyde (25uC, 10 min) in PBS, and stopped with
0.125M Glycine. Chromatin immunoprecipitation (ChiP) was
performed as described previously [72]. Nuclei were sonicated
using a Diagenode Bioruptor (Liege, full power 30 s on, 30 s off, in
an icebath for 50 min) to produce fragments of ,300 bp. An
arbitrary concentration of 200 mg chromatin was incubated with
4 mg rabbit IgG (Santa Cruz, sc-2025), Psip1 antibodies (A300-
847), H3K36me3 antibodies (Abcam, Ab 9050-100), aH3K4me3
(Millipore 07-473) or aSRSF1 (Invitrogen 32-4500) and washed,
eluted and cross-links reversed.
Histone association assay
To analyze proteins associated with H3K36me3, aH3K36me3
ChIP’ed chromatin was heated at 95 C in the presence of 16
Laemmli buffer for 10 min, separated on 4–20% SDS-PAGE,
transferred onto a PVDF membrane, and probed with aSRSF1, a
SRSF2, aSRSF3, aPTB (Invitrogen 32-4800) aPsip1 (A300-847A),
and aH3K36me3 antibodies. Instead of species-specific secondary
antibodies, HRP coupled Clean-Blot IP Detection Reagent
(Thermo Scientific Prod. No. 21230) was used to avoid cross
reactivity of HRP coupled antibody to denatured IgGs in the gel.
ChiP on chip for Psip1, H3K36me3, H3K4me3, and Srsf1
For analysis in Figure 2, WGA2 amplified ChIP DNA and input
DNA were labeled and hybridized according to the manufacturer’s
protocol to a 36720,000 probe custom microarray containing
specific tiled regions encompassing 8.2 megabases of the mouse
genome (Nimblegen). Array platform number is GPL13276 and the
GEO accession numbers for ChIP data are; Psip1: GSM697402,
GSM697403,GSM697404,GSM697405,H3K36me3:GSM697406,
GSM697407, GSM697408, GSM697409, H3K4me3: GSM697410-
GSM697411.
Biological replicates were performed for all the ChIP array
experiments and the data were analyzed in R/Bioconductor
(http://genomebiology.com/2004/5/10/R80) using the Epigenome
(PROT43) protocol (http://www.epigenome-noe.net/WWW/
researchtools/protocol.php?protid=43) with the following
parameters; The mean signal intensity of the 4 replicate probes
present on each array was calculated. Loess normalization was used
within arrays to correct for dye bias, and scale normalization was
used within replicate groups to control inter-array variability. Log
enrichment for each group was calculated by subtracting the mean
log2 input intensities from the mean of log2 ChIP-enriched
intensities. Probes were tested for significant enrichment using the
significance analysis of microarrays (SAM) technique [73], and the
local false discovery rate based on the SAM statistic was calculated
using the Locfdr R package [74]. A false discovery rate of 0.05 was
used as the significance cutoff. The spearman rank correlation
coefficient was used to assess the correlation between replicate
experiments.
The spearman rank correlation coefficient was used on all log
enrichment scores between data from Psip1 ChIP and remaining
groups to determine, significance and strength of their relationship.
To determine if overlaps between Psip1, H3K36me3 and
H3K4me3 enriched probes were significant, 1000 randomized
datasets were produced and the 95th percentile of the resultant
overlaps was used as a significance cutoff.
To determine the enrichment of probes over genomic features,
probes were selected based on the following criteria. Genes were
classified as expressed in MEF if they had been detected on an
Illumina microarray (unpublished data) with a p value of detection
,0.01. Genes classified as non-expressed in MEF cells were
defined if they had a p value of detection .0.5 and a signal
intensity less than 0. Only those genes that contained significantly
enriched Psip1/p52 and H3K36 me3 signal were used for analysis.
Exonic probes were defined as those that fall within an exon -
probes falling within the 59UTR and ,200 bp from TSS were
excluded. Intronic regions were defined as those that fall within an
intron and .200 bp from the intron start or end site. Intergenic
regions probes were selected from probes that are more than
1 Kbp from either the transcriptional start sites or transcriptional
end sites of a gene. The significance of differences between
genomic regions was calculated using a Wilcoxon rank sum test,
with a p value cutoff ,0.05.
For data in Figure 6, WGA2 amplified ChIP DNA and input
DNA were labeled and hybridized to a 36720,000 probe custom
microarray containing specific tiled regions encompassing 8.2
megabases of the mouse genome (Nimblegen). Array platform
number is GPL14175 and the GEO accession numbers for ChIP
data are; Psip1: GSM782590, H3K36me3: GSM782591, Srsf1
(Wt MEFs): GSM782592, GSM782593, Srsf1 (Psip1
2/2 MEFs):
GSM782594, GSM782595.
The median signal of replicate probes was taken prior to
normalization. Data was normalized as above. Because levels of
Srsf1 binding were generally quite low we used quantized
correlation coefficients (QCC), which are less effected by the
amount of binding signal present in the data, to determine the
correlation between replicate experiments [75]. Across the entire
Figure 6. ChIP for H3K36me3, Psip1, and Srsf1 in wt and Psip1 mutant MEFs. A) Mean log2 ChIP:input for H3K36me3, Psip1 and Srsf1 in wt
MEFs across the Vcan (A), Diap2 (B) and Ppfibp1 (C) loci. Distribution of Srsf1 in chromatin from Psip1
2/2 MEFs is also shown. Filled boxes indicate the
positions of exons and the arrows indicate the position of alternatively spliced exons whose inclusion into spliced mRNAs is altered in Psip1
gt/gt cells.
n=2 biological replicates that also incorporate a technical (dye-swap) replicate. Array platform number is GPL14175 and the GEO accession numbers
for ChIP data are; GSM782590 (Psip1), GSM782591 (H3K36me3), GSM782592 and GSM782593 (Srsf1 in wt), GSM782594 and GSM782595 (Srsf1 in
Psip1
2/2).
doi:10.1371/journal.pgen.1002717.g006
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and 0.18 in Psip1
2/2 cells likely reflecting a loss of overall Srsf1
binding captured in the mutant cells. However, considering only
the regions on the array around exons, where most Srsf1 binding is
likely to be located, the QCC in wild-type cells rises to 0.5 and to
0.23 in mutant cells. Enriched probes were identified as those
above a threshold defined using the upperBoundNull method from
Ringo Bioconductor Package [76]. Probes above the threshold
must also be located within 300 bp of 2 or more probes to be
called enriched. A hypergeometric test was applied to determine
significant overlap between enriched probe groups.
Nuclear extract preparation and immunoprecipitation
from NIH 3T3 cells
Nuclear extract was prepared from NIH 3T3 cells according to
[77] with the following modifications: after precipitation with
1/10th vol of 4 M (NH4)2SO4 and mixingfor 20 min, the lysate was
cleared by centrifugation at 116000g in a TL-100 ultracentrifuge
(Beckman, Mountain View, CA). The supernatant was dialyzed
against 3 changes of buffer C (25 mM Hepes pH 7.6, 150 mM
KCl, 12.5 mM MgCl2, 0.1 mM EDTA, 10% (v/v) glycerol, 1 mM
DTT, 0.2 mM PMSF and complete protease inhibitors (Roche))
and flash frozen in liquid nitrogen. The extracts were quantified by
Bradford assay (Bio-Rad). A total of 200 mg nuclear extract were
immunoprecipitated by incubation for 45 minutes at 4uC with 5 mg
rabbit IgG (Santa Cruz, sc-2027) or aPSIP1 p52/p75 (A300-847) or
a-p75 (A300-348) together with 10 ml Protein A Dynal beads. After
washingthree times with buffer C, butcontaining200 mM KCl, for
10 min each, the bound proteins were boiled in SDS sample buffer,
separated on a 4–20% tris glycine polyacrylamide gel and either
stained with colloidal coomassie (Invitrogen) to identify the proteins,
or transferred to nitrocellulose membrane for western blotting.
Individual protein bands or 1 cm
2 gel pieces were cut and subjected
to mass spectrometry analysis.
MS/MS analysis
Excised gel pieces were treated with trypsin at 37uC and the
peptides extracted with 10% formic acid. Peptides were separated
using an UltiMate nanoLC (LC Packings, Amsterdam) equipped
with a PepMap C18 trap & column. The eluent was sprayed into a
Q-Star XL tandem mass spectrometer (Applied Biosystems, Foster
City, CA) and analyzed in Information Dependent Acquisition
(IDA) mode, performing 1 s of MS followed by 3 s MSMS
analyses of the 2 most intense peaks seen by MS. The MS/MS
data file generated was analyzed using the Mascot 2.1 search
engine (Matrix Science, London, UK) against UniProt April 2009
(7966092 sequences) or NCBInr March 2010 (10530540 sequenc-
es) databases with no species restriction. The data was searched
with tolerances of 0.2 Da for the precursor and fragment ions. The
Mascot search results were accepted if a protein hit included at
least 2 peptides with a score above the homology threshold.
In vitro pulldowns
For p52 pulldown, T7 tagged SRSF1, SRSF3 and RG and RD
mutants of SRSF1 and GFP- SRSF2, were overexpressed in 293T
cells [49,78], and the cell lysates incubated with Glutathione beads
coupled with p52 in GST lysis buffer. Unbound proteins were
washed 5 times with the same buffer. Bound proteins were
separated on 12% SDS PAGE. After transferring to nitrocellulose
membrane, the proteins were probed with aT7 monoclonal
antibody (Novagen) and imaged.
For histone pulldowns, 1 mg of T7 tagged SRSF1, purified from
293T cells,wasincubated with T7beads inGSTlysisbufferfor1 hr
at 4uC. After washing unbound proteins in same buffer, 1 mgo f
GST-p52 and 1 mg HeLa core histones (Active motif, cat. 53501)
were added and incubated for 3 hrs. Unbound proteins were
washed off 5 times with the same buffer and bound proteins were
separated on 17% SDS-PAGE. After transferring to nitrocellulose
membrane, the proteins were probed with aH3K36me3 antibodies
and imaged. The membrane was then stripped and reprobed with
aH3K9me2 and aH3K4me3 antibodies.
Immunofluorescence
Cells grown on slides were fixed in 3% paraformaldheyde (pFa)
as previously described [79] and incubated with primary
antibodies; rabbit A300-847(1:200 dilution, Bethyl laboratories,)
which recognizes an epitope (a.a. 225–275) present in both p52
and p75, A300-848(1:200, Bethyl laboratories) which recognizes
only p75 (a.a. 480–530), mouse monoclonal aSc35 (1:50, Sigma
S4045). Secondary antibodies, and image capture by wide-field
epifluorescence microscopy were as previously described [79].
Confocal analysis was performed using a Zeiss LSM510 confocal
microscope.
Alternative splicing microarray
Microarray analysis of alternative splicing was performed as
described [53]. Five hundred gg total RNA, isolated from primary
MEFs derived from three littermates of E13.5 wild-type or Psip1
gt/gt
embryos [22], were used to generate sense-strand cDNA (Ambion
WT expression kit #411974). Purified cDNA was fragmented and
labelled with biotin-conjugated nucleotides using terminal transferase
(Affymetrix, #900670). Arrays were hybridized with labelled cDNA
for 16 h at 50uC in 7% dimethylsulfoxide. Washing and detection
were performed in an Affymetrix Fluidics Station using standard
protocols for eukaryotic targets [53]. Scanned microarrays were
analyzed using ASPIRE3 (Analysis of SPlicing Isoform Reciprocity,
version 3) [52], which predicts splicing changes from reciprocal sets of
microarray probes that recognize either inclusion or skipping of an
alternative exon. Data werequantified as the change in the fraction of
exon inclusion (DI), where a value of 1.0 indicates a 100% increase,
and 21.0 a 100% decrease in exon inclusion.
RT–PCR
Primers corresponding to exons flanking the alternate spliced
exons were designed (Table S2). 5 mg of RNA was reverse
transcribed with superscript reverse transcriptase II (Invitrogen)
using random primers, and each of the forward primers were
labeled with
32P c-ATP. PCR was performed for 24–30 cycles,
and the products were separated on a 5% denaturing polyacryl-
amide gel and analyzed by autoradiography for 3–16 h. or
separated on 1.5% agarose gel,
Supporting Information
Figure S1 A300-847 antibody immunoprecipitates from wild-
type and mutant cells. A) Silver-stained gel of immunoprecipitates
with IgG, and A300-847 antibodies (anti Psip1-p52/p75) from
nuclear extracts prepared from wild-type and Psip1
gt/gt MEFs, 5%
of the nuclear extract was loaded as input. Duplicate gel was
stained with colloidal coomassie (Invitrogen), and 1 cm
2 of the
lanes corresponding to molecular weight of 25-40 KDa (indicated
by boxed area) were subjected to mass spectrometry. Srsf1, Srsf5
and hnRNPm were identified from I.P with wild-type nuclear
extract, but not from I.P with Psip1
gt/gt nuclear extract. B)
Western blot of A300-847 IPs from wild-type and Psip1
gt/gt (A)
with anti Srsf1.
(PDF)
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modifications. Cells highlighted with yellow are with specificity
factor .2, and were used to generate Figure 1C.
(XLSX)
Table S2 Alternative splicing array results in Excel spread sheets
(Sheet 1 includes data from all the exons on the array, Sheet 2
includes only exons which shows significant changes in alternative
splicing between wild-type and Psip1gt/gt cells, Sheet 3 includes the
annotation for the data. Related to Figure 5.
(XLS)
Table S3 Sequence of PCR primers used for RT-PCR
validation of alternative splicing events in wild-type, Psip1
gt/gt,
and Psip
2/2 cells.
(DOCX)
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